Groundbreaking PTSD Study by McLean Researchers Among NIH Director’s Top Science Highlights of 2024
March 19, 2025
In a landmark recognition, a study led by Nikolaos P. Daskalakis, MD, PhD, and Kerry J. Ressler, MD, PhD, of McLean Hospital was recently featured in the National Institutes of Health (NIH) Director’s Top Science Highlights of 2024.
The study, which delves into the biological underpinnings of post-traumatic stress disorder (PTSD), represents a significant leap forward in understanding and addressing this complex mental health condition.
PTSD, a debilitating disorder affecting millions worldwide, often arises following exposure to traumatic events. Despite its prevalence, the mechanisms driving PTSD remain elusive, hindering the development of targeted treatments.
The McLean-led research, however, provides groundbreaking insights into how trauma impacts the brain and body, offering new avenues for therapeutic interventions.
“This recognition from the NIH underscores the importance of advancing our understanding of PTSD at the biological level,” said Ressler, chief scientific officer at McLean Hospital and a globally recognized expert in trauma research.
“Our work highlights the potential for precision medicine to transform care for individuals living with the long-term effects of trauma.”
The study leverages cutting-edge genomic and neurobiological techniques to identify biomarkers associated with PTSD. By analyzing brain samples and genetic data, the researchers were able to pinpoint specific pathways affected by trauma. These discoveries could lead to the development of novel treatments aimed at addressing the root causes of PTSD rather than simply managing symptoms.
Daskalakis, director of McLean’s Neurogenomics and Translational Research Laboratory, emphasized the collaborative nature of the work. “This study was only possible because of the incredible partnership between our clinical and research teams. Together, we are building a bridge between the lab and the clinic to deliver real-world impact for patients.”
One of the most promising aspects of the research is its focus on personalized treatment approaches. The findings suggest that individuals may respond differently to trauma due to variations in their genetic and biological makeup. Understanding these differences could pave the way for tailored therapies that are more effective and have fewer side effects.
The NIH Director’s recognition places this study among the most influential scientific achievements of the year, spotlighting the critical role of research in improving mental health care.
For McLean Hospital, the acknowledgment is a testament to its commitment to advancing psychiatric research and translating discoveries into meaningful patient outcomes.
“This is not just a victory for science,” said Ressler, “but for the millions of people living with PTSD who stand to benefit from new, life-changing treatments.”
